200,000 "frozen people" gospel! Domestic innovative therapeutic drugs have been approved for market

"Pharmaceutical network industry dynamics" recently, the domestic "frozen people" ushered in the gospel.
The State Drug Administration has approved a new adaptation for the treatment of amyotrophic lateral sclerosis in Nanjing Synthesizer Dongyuan Pharmaceutical Co., Ltd. (Idarafeng injection, including 5ml:10mg, 20ml:30mg).
"Amyotrophic lateral sclerosis" (ALS), commonly known as "frozen human disease", is a rare disease in the world, patients will muscular dystrophy, prone to fatigue, and even feel weak, the body as if "frozen".
, it is ranked among the top five terminal diseases listed by WHO, with most patients surviving for only three to five years.
present, there are about 200,000 people with freezing disease in China, most of whom are distributed, about 10% family-owned, the age of onset is mostly between 30 and 60 years old, more men than women.
a long time, the treatment of freezing disease is limited, there is evidence-based evidence, can delay the development of freezing disease of the drug only Liluazine and Idalafeng.
idalatin is a free-form sculven agent that can reduce oxidative stress, which is an important factor in the occurrence and progression of ALS.
2015, Japan and South Korea approved Idara for treatment of freezing human disease.
FDA, based on clinical trial results in Japan, determined the efficacy of Ida Lafon and approved it in May 2017 for the treatment of freezing human disease.
understood that, as of now, Ida Lafeng has been in Japan, South Korea, the United States, Canada, China and other countries have been approved for the treatment of ALS.
Sound Pharmaceuticals was approved this time is also the world's second, domestic first listed Ida Lafeng injection, because the drug has been used for a long time to treat acute ischemic stroke, has accumulated a large number of clinical experience, good safety.
it is worth mentioning that, in addition to freezing disease, since its listing, the clinical advantages of Idara for stroke treatment have been recognized by many guidelines and consensus at home and abroad.
Includes, but is not limited to, the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China issued by the Chinese Medical Association in 2010, 2015 and 2018; Clinical Pathways to Death (2016), Clinical Pathways to Cerebral Hemorrhage (2016 Edition) and Guidelines for The Treatment of Acute Stages of Ischemic Stroke (2017 Edition);
Pioneer Pharmaceuticals is a rapidly transforming pharmaceutical company driven by innovation and research and development, ranking among the "Top 10 Chinese Innovative Pharmaceutical Companies" and "Top 100 Pharmaceutical Industry in China" for many years.
June 10, Synsheng Pharmaceuticals submitted its application for listing on the Main Board to the Hong Kong Stock Exchange.
July 30, the first class of innovative drug in the field of cerebrovascular diseases, developed by Synological Pharmaceuticals, was approved for listing with a strong solution for rightol injection.
Idara feng rightol injection with a thick solution to remove free fundamentals, anti-inflammatory and protect the blood-brain barrier and other multiple mechanisms, synergy, reduce acute ischemic stroke caused by brain nerve damage, for the treatment of stroke patients in China has also brought new options.
with the approval of the drug for the treatment of frozen people, the industry believes that it is expected to help people with freezing disease, especially in the country, the progression of the disease to extend survival and improve quality of life.